Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$1.17 USD
-0.10 (-7.87%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.17 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Adaptimmune Therapeutics PLC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 60 | 27 | 6 | 4 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 60 | 27 | 6 | 4 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 200 | 191 | 168 | 137 | 141 |
Income After Depreciation & Amortization | -140 | -164 | -162 | -133 | -140 |
Non-Operating Income | 27 | 1 | 5 | 3 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -113 | -163 | -157 | -130 | -137 |
Income Taxes | 1 | 3 | 1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -114 | -165 | -158 | -130 | -137 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -114 | -165 | -158 | -130 | -137 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -130 | -158 | -156 | -126 | -132 |
Depreciation & Amortization (Cash Flow) | 10 | 6 | 7 | 8 | 8 |
Income After Depreciation & Amortization | -140 | -164 | -162 | -133 | -140 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 201.07 | 161.21 | 155.81 | 142.46 | 104.97 |
Diluted EPS Before Non-Recurring Items | -0.63 | -1.02 | -1.02 | -0.90 | -1.32 |
Diluted Net EPS (GAAP) | -0.54 | -1.02 | -1.02 | -0.90 | -1.32 |
Fiscal Year end for Adaptimmune Therapeutics PLC falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 5.68 | 0.23 | 7.32 | 5.13 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 5.68 | 0.23 | 7.32 | 5.13 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 54.94 | 50.09 | 53.95 | 50.04 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -49.26 | -49.86 | -46.63 | -44.91 |
Non-Operating Income | NA | 1.28 | 1.28 | 1.72 | 24.20 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -47.98 | -48.57 | -44.91 | -20.71 |
Income Taxes | NA | 0.53 | -0.66 | 0.69 | 0.68 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -48.50 | -47.92 | -45.60 | -21.39 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -48.50 | -47.92 | -45.60 | -21.39 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 241.87 | 227.11 | 226.31 | 184.70 |
Diluted EPS Before Non-Recurring Items | NA | -0.18 | -0.24 | -0.20 | -0.21 |
Diluted Net EPS (GAAP) | NA | -0.20 | -0.22 | -0.20 | -0.12 |